Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Implementation of wide-scale pharmacogenetic testing in primary care.

Natasha Petry, Baye J, Aifaoui A, Wilke RA, Lupu RA, Savageau J, Gapp B, Massmann A, Hahn D, Hajek C, Schultz A.

Pharmacogenomics. 2019 Aug;20(12):903-913. doi: 10.2217/pgs-2019-0043.

PMID:
31453774
2.

Chronic Kidney Disease in Agricultural Communities.

Wilke RA, Qamar M, Lupu RA, Gu S, Zhao J.

Am J Med. 2019 Oct;132(10):e727-e732. doi: 10.1016/j.amjmed.2019.03.036. Epub 2019 Apr 15. Review.

PMID:
30998912
3.

CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors.

Petry N, Lupu R, Gohar A, Larson EA, Peterson C, Williams V, Zhao J, Wilke RA, Hines LJ.

Pharmacogenomics. 2019 Apr;20(5):343-351. doi: 10.2217/pgs-2018-0156. Epub 2019 Apr 15.

PMID:
30983508
4.

Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction.

Zhao J, Feng Q, Wu P, Lupu RA, Wilke RA, Wells QS, Denny JC, Wei WQ.

Sci Rep. 2019 Jan 24;9(1):717. doi: 10.1038/s41598-018-36745-x.

5.

Fatty acid synthase is required for profibrotic TGF-β signaling.

Jung MY, Kang JH, Hernandez DM, Yin X, Andrianifahanana M, Wang Y, Gonzalez-Guerrico A, Limper AH, Lupu R, Leof EB.

FASEB J. 2018 Jul;32(7):3803-3815. doi: 10.1096/fj.201701187R. Epub 2018 Feb 16.

6.

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells.

Corominas-Faja B, Cuyàs E, Lozano-Sánchez J, Cufí S, Verdura S, Fernández-Arroyo S, Borrás-Linares I, Martin-Castillo B, Martin ÁG, Lupu R, Nonell-Canals A, Sanchez-Martinez M, Micol V, Joven J, Segura-Carretero A, Menendez JA.

Carcinogenesis. 2018 Apr 5;39(4):601-613. doi: 10.1093/carcin/bgy023.

7.

Pharmacogenetics - The Year in Review.

Lupu RA, Wilke RA.

S D Med. 2017 Dec;70(12):533-534. No abstract available.

PMID:
29334439
8.

Fatty acid synthase (FASN) as a therapeutic target in breast cancer.

Menendez JA, Lupu R.

Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016. doi: 10.1080/14728222.2017.1381087. Epub 2017 Sep 21. Review.

PMID:
28922023
9.

An ultrahot gas-giant exoplanet with a stratosphere.

Evans TM, Sing DK, Kataria T, Goyal J, Nikolov N, Wakeford HR, Deming D, Marley MS, Amundsen DS, Ballester GE, Barstow JK, Ben-Jaffel L, Bourrier V, Buchhave LA, Cohen O, Ehrenreich D, García Muñoz A, Henry GW, Knutson H, Lavvas P, Etangs ALD, Lewis NK, López-Morales M, Mandell AM, Sanz-Forcada J, Tremblin P, Lupu R.

Nature. 2017 Aug 2;548(7665):58-61. doi: 10.1038/nature23266.

PMID:
28770846
10.

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1221-1227. doi: 10.1007/s00280-017-3322-9. Epub 2017 May 5.

PMID:
28477227
11.

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Cuyàs E, Corominas-Faja B, Martín MM, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.

Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.

12.

Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells.

Menendez JA, Lupu R.

Oncogenesis. 2017 Feb 27;6(2):e299. doi: 10.1038/oncsis.2017.4.

13.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.

Corominas-Faja B, Vellon L, Cuyàs E, Buxó M, Martin-Castillo B, Serra D, García J, Lupu R, Menendez JA.

Histol Histopathol. 2017 Jul;32(7):687-698. doi: 10.14670/HH-11-830. Epub 2016 Oct 7.

14.

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.

Menendez JA, Vellon L, Espinoza I, Lupu R.

Oncoscience. 2016 Jul 22;3(7-8):242-257. eCollection 2016.

15.

Decreasing the critical value of hemoglobin required for physician notification reduces the rate of blood transfusions.

Larson EA, Thompson PA, Anderson ZK, Anderson KA, Lupu RA, Tigner V, Hoffman WW.

Int J Gen Med. 2016 Jun 3;9:133-6. doi: 10.2147/IJGM.S96248. eCollection 2016.

16.

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.

Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA.

Oncotarget. 2016 Aug 16;7(33):52974-52992. doi: 10.18632/oncotarget.9732.

17.

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer.

Gonzalez-Guerrico AM, Espinoza I, Schroeder B, Park CH, Kvp CM, Khurana A, Corominas-Faja B, Cuyàs E, Alarcón T, Kleer C, Menendez JA, Lupu R.

Oncotarget. 2016 Nov 1;7(44):71151-71168. doi: 10.18632/oncotarget.9463.

18.

Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.

Colomer R, Sarrats A, Lupu R, Puig T.

Curr Drug Targets. 2017;18(2):147-159. doi: 10.2174/1389450117666160112113930. Review.

PMID:
26758667
19.

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres.

Menendez JA, Benboudjema L, Vellon L, Rubio MA, Espinoza I, Campisi J, Lupu R.

Oncotarget. 2015 Nov 24;6(37):39408-21. doi: 10.18632/oncotarget.4962.

20.

Heregulin, a new regulator of telomere length in human cells.

Menendez JA, Rubio MA, Campisi J, Lupu R.

Oncotarget. 2015 Nov 24;6(37):39422-36. doi: 10.18632/oncotarget.4964.

21.

Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.

Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv090. doi: 10.1093/jnci/djv090. Print 2015 Jun.

PMID:
25888715
22.

Terrestrial aftermath of the Moon-forming impact.

Sleep NH, Zahnle KJ, Lupu RE.

Philos Trans A Math Phys Eng Sci. 2014 Sep 13;372(2024):20130172. doi: 10.1098/rsta.2013.0172.

PMID:
25114303
23.

CCN1 promotes vascular endothelial growth factor secretion through αvβ 3 integrin receptors in breast cancer.

Espinoza I, Menendez JA, Kvp CM, Lupu R.

J Cell Commun Signal. 2014 Mar;8(1):23-7. doi: 10.1007/s12079-013-0214-6. Epub 2013 Dec 12. No abstract available.

24.

Heregulin in breast cancer: old story, new paradigm.

Khurana A, Gonzalez-Guerrico A, Lupu R.

Curr Pharm Des. 2014;20(30):4874-8. Review.

PMID:
24283953
25.

Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.

Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T, Vellon L, Iglesias JM, Leis O, Martín ÁG, Vazquez-Martin A, Menendez JA.

Cell Cycle. 2013 Sep 15;12(18):3109-24. doi: 10.4161/cc.26173. Epub 2013 Aug 21.

26.

A dust-obscured massive maximum-starburst galaxy at a redshift of 6.34.

Riechers DA, Bradford CM, Clements DL, Dowell CD, Pérez-Fournon I, Ivison RJ, Bridge C, Conley A, Fu H, Vieira JD, Wardlow J, Calanog J, Cooray A, Hurley P, Neri R, Kamenetzky J, Aguirre JE, Altieri B, Arumugam V, Benford DJ, Béthermin M, Bock J, Burgarella D, Cabrera-Lavers A, Chapman SC, Cox P, Dunlop JS, Earle L, Farrah D, Ferrero P, Franceschini A, Gavazzi R, Glenn J, Solares EA, Gurwell MA, Halpern M, Hatziminaoglou E, Hyde A, Ibar E, Kovács A, Krips M, Lupu RE, Maloney PR, Martinez-Navajas P, Matsuhara H, Murphy EJ, Naylor BJ, Nguyen HT, Oliver SJ, Omont A, Page MJ, Petitpas G, Rangwala N, Roseboom IG, Scott D, Smith AJ, Staguhn JG, Streblyanska A, Thomson AP, Valtchanov I, Viero M, Wang L, Zemcov M, Zmuidzinas J.

Nature. 2013 Apr 18;496(7445):329-33. doi: 10.1038/nature12050.

27.

Outcome of nicotine replacement therapy in patients admitted to ICU: a randomized controlled double-blind prospective pilot study.

Pathak V, Rendon IS, Lupu R, Tactuk N, Olutade T, Durham C, Stumacher R.

Respir Care. 2013 Oct;58(10):1625-9. doi: 10.4187/respcare.01791. Epub 2013 Mar 26.

28.

The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.

Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, Joven J, Lupu R, Menendez JA.

Cell Cycle. 2013 Jan 15;12(2):207-18. doi: 10.4161/cc.23352. Epub 2012 Jan 15. Review.

29.

Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers.

Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J.

Clin Cancer Res. 2012 Jul 1;18(13):3658-67. doi: 10.1158/1078-0432.CCR-11-2857. Epub 2012 May 9.

30.

Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.

Lupu-Meiri M, Geras-Raaka E, Lupu R, Shapira H, Sandbank J, Segal L, Gershengorn MC, Oron Y.

J Cell Physiol. 2012 Nov;227(11):3621-8. doi: 10.1002/jcp.24068.

31.

CCN1, a candidate target for zoledronic acid treatment in breast cancer.

Espinoza I, Liu H, Busby R, Lupu R.

Mol Cancer Ther. 2011 May;10(5):732-41. doi: 10.1158/1535-7163.MCT-10-0836. Epub 2011 Mar 10.

32.

Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.

Eldar-Boock A, Miller K, Sanchis J, Lupu R, Vicent MJ, Satchi-Fainaro R.

Biomaterials. 2011 May;32(15):3862-74. doi: 10.1016/j.biomaterials.2011.01.073. Epub 2011 Mar 4.

33.

The detection of a population of submillimeter-bright, strongly lensed galaxies.

Negrello M, Hopwood R, De Zotti G, Cooray A, Verma A, Bock J, Frayer DT, Gurwell MA, Omont A, Neri R, Dannerbauer H, Leeuw LL, Barton E, Cooke J, Kim S, da Cunha E, Rodighiero G, Cox P, Bonfield DG, Jarvis MJ, Serjeant S, Ivison RJ, Dye S, Aretxaga I, Hughes DH, Ibar E, Bertoldi F, Valtchanov I, Eales S, Dunne L, Driver SP, Auld R, Buttiglione S, Cava A, Grady CA, Clements DL, Dariush A, Fritz J, Hill D, Hornbeck JB, Kelvin L, Lagache G, Lopez-Caniego M, Gonzalez-Nuevo J, Maddox S, Pascale E, Pohlen M, Rigby EE, Robotham A, Simpson C, Smith DJ, Temi P, Thompson MA, Woodgate BE, York DG, Aguirre JE, Beelen A, Blain A, Baker AJ, Birkinshaw M, Blundell R, Bradford CM, Burgarella D, Danese L, Dunlop JS, Fleuren S, Glenn J, Harris AI, Kamenetzky J, Lupu RE, Maddalena RJ, Madore BF, Maloney PR, Matsuhara H, Michaowski MJ, Murphy EJ, Naylor BJ, Nguyen H, Popescu C, Rawlings S, Rigopoulou D, Scott D, Scott KS, Seibert M, Smail I, Tuffs RJ, Vieira JD, van der Werf PP, Zmuidzinas J.

Science. 2010 Nov 5;330(6005):800-4. doi: 10.1126/science.1193420.

34.

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.

Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M.

Int J Cancer. 2009 Nov 1;125(9):2004-13. doi: 10.1002/ijc.24648.

35.

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.

Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R.

Biochem Biophys Res Commun. 2009 Jul 31;385(3):454-9. doi: 10.1016/j.bbrc.2009.05.085. Epub 2009 May 23.

PMID:
19467222
36.

[Wireless device for monitoring the patients with chronic disease].

Ciorap R, Zaharia D, Corciovă C, Ungureanu M, Lupu R, Stan A.

Rev Med Chir Soc Med Nat Iasi. 2008 Oct-Dec;112(4):1115-9. Romanian.

PMID:
20209797
37.

[Monitoring system for cardiovascular parameters of drivers].

Ciorap R, Zaharia D, Corciovă C, Ungureanu M, Lupu R.

Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):263-5. Romanian.

PMID:
18677939
38.
39.

Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1.

Deshet N, Lupu-Meiri M, Espinoza I, Fili O, Shapira Y, Lupu R, Gershengorn MC, Oron Y.

J Cell Physiol. 2008 Sep;216(3):632-9. doi: 10.1002/jcp.21441.

PMID:
18366077
40.

Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.

Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA.

Cell Prolif. 2008 Feb;41(1):59-85. doi: 10.1111/j.1365-2184.2007.00498.x.

PMID:
18211286
41.

Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?

Colomer R, Lupu R, Papadimitropoulou A, Vellón L, Vázquez-Martín A, Brunet J, Fernández-Gutiérrez A, Segura-Carretero A, Menéndez JA.

Clin Transl Oncol. 2008 Jan;10(1):30-4.

PMID:
18208790
42.
44.

Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.

Menendez JA, Lupu R.

Nat Rev Cancer. 2007 Oct;7(10):763-77. Review.

PMID:
17882277
45.

Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.

Menendez JA, Lupu R.

J Clin Oncol. 2007 Jun 10;25(17):2496-8; author reply 2499. No abstract available.

PMID:
17557968
47.
50.

Supplemental Content

Support Center